From: Reducing stillbirths: prevention and management of medical disorders and infections during pregnancy
Basic science and physiological studies |
---|
   • Mechanisms of causation of hypertensive disorders of pregnancy and how these cause stillbirths* |
   • Auto-immune pathophysiology in stillbirth causation |
   • Association of periodontal disease with pre-eclampsia and pathophysiology of subsequent stillbirth* |
   • Dynamics of stillbirth causation in intrahepatic cholestasis |
   • Drug safety and efficacy studies: |
â—¦ Anti-malarials in pregnancy |
â—¦ Drugs for intrahepatic cholestasis |
â—¦ Non-penicillin treatments for syphilis |
â—¦ Antibiotic use in pregnancy |
   • Identification of other unknown risk factors |
   • Prevalence of uterine abnormalities in low-/middle-income countries |
Pilot/cohort studies of interventions |
   • New approaches for PIH and chronic hypertension management in community settings* |
   • Management protocols for HIV and syphilis co-infection |
   • Management of penicillin drug allergy in community settings |
   • Diagnosis and surgical repair of uterine abnormalities in women with recurrent fetal loss |
   • Intravenous immunoglobulin treatment (compared to heparin, aspirin, or other anti-coagulants) in selected populations with recurrent pregnancy loss and antiphospholipid antibodies |
Well-designed large RCTs of interventions powered to detect stillbirths |
   • Periodontal care studies powered to detect impact on stillbirth rates* |
   • Calcium supplementation to prevent PIH and pre-eclampsia in deficient populations |
   • Anti-oxidant supplementation in deficient populations |
   • Management of intrahepatic cholestasis including nonstress test, amniotic fluid index, meconium screening and early delivery |
   • Calcium supplementation in high-risk pregnancies* |
   • Antibiotics for pPROM* |
Effectiveness trials in large populations/at scale |
   • Maternal anti-helminthic treatment: impact on maternal anaemia and stillbirth* |
   • On-site syphilis testing and treatment |
   • ITNs for Plasmodium vivax and in lower-transmission settings (Asia and Latin America) |